Abstract: There is provided an endoglucanase enzyme, which is useful for reducing fuzz of regenerated cellulose-containing fabrics, improving the touch and appearance, color clarification, localized variation in color, reducing stiffness and using it as components of a detergent, as well as deinking waste paper and improving freeness of paper pulp. A cDNA coding for the endoglucanase enzyme NCE5 was cloned and its DNA sequence and amino acid sequence derived from it were determined.

Abstract: There are provided a stick type expanded starch confectionery with a wave-like configuration on its surface and a process for easily manufacturing the same, which uses an extruder method. According to the process, the stick type expanded starch confectionery is obtained by adjusting amounts of water and calcium salt to an amount of starch raw material to prepare a dough, whereby fluidity of thermally treated dough extruded from a double-staged die which belongs to an extruder is controlled.

Abstract: Novel carbapenem derivatives, represented by the following formula (I), having a substituted or unsubstituted imidazo[5,1-b]thiazolium-6-ylmethyl group at the 2-position are disclosed. The compounds represented by the formula (I) have potent antibacterial activity against a wide spectrum of bacteria from Gram-positive bacteria to Gram-negative bacteria including Pseudomonas aeruginosa and, in addition, have potent antibacterial activity against various .beta.-lactamase-producing bacteria and MRSA and are very stable against DHP-1.

Abstract: A .gamma.-diketone compound represented by the following formula (I) and a pharmaceutically acceptable salt and solvate thereof having platelet aggregation inhibitory activity is disclosed: ##STR1## wherein B is --Z--(CH.sub.2).sub.q COOR.sup.

Abstract: Compounds, represented by the following formula (I), having a .beta.-(substituted or unsubstituted imidazo?5,1-b!thiazolyl)vinyl group at the 3-position of the cephem ring and a salt and an ester thereof are disclosed. The compounds have antibacterial activity against a very wide spectrum of bacteria and potent antibacterial activity against Gram-positive bacteria, Gram-negative bacteria, and resistant bacteria. ##STR1## wherein X represents CH or N, R.sup.1 represents a hydrogen atom or an amino protective group, R.sup.2 represents a hydrogen atom, a C.sub.1-6 alkyl group, a C.sub.3-7 cycloalkyl group, or a hydroxy protective group, R.sup.3 is absent or represents a hydrogen atom, a salt forming cation, or a carboxyl protective group, R.sup.4, R.sup.5, and R.sup.6, which may be the same or different, each independently represent a hydrogen atom or a C.sub.1-6 alkyl group, R.sup.7+ is absent or a cation of a C.sub.1-6 alkyl, and n is an integer of 0 to 1.

Abstract: Compounds of formulae (II), (III), (IV) and (V) or salts thereof are intermediates for pharmacologically active tricyclic benzazepine and benzothiazepine derivatives, ##STR1## wherein R represents hydrogen, alkyl, phenylalkyl, or a protective group of a triazole ring, R.sup.1 -R.sup.5 represent hydrogen, alkyl, alkenyl, alkoxy, amino, oxim or hydroxyl, and R.sup.41 represents hydrogen, C.sub.1-6 alkyl which may be optionally substituted, or a protective group for a carboxyl group.

Abstract: A compound represented by the general formula (I) and a pharmaceutically acceptable salt and solvate thereof having an effect for inhibiting the aggregation of platelets is disclosed: ##STR1## wherein A, B and C represent independently CH.sub.2 or C.dbd.O;X and Y are different from each other, and each of them is CH or N;D is --(CH.sub.2).sub.k -- or --(CH.sub.2).sub.m --CO-- where k is an integer of 1 to 4; and m is an integer of 0 to 3;E is the following group (II) or (III): ##STR2## wherein n is an integer of 1 to 3; and Z is --W--(CH.sub.2).sub.p --COOR.sup.3 (wherein W is --O-- or a bond; p is an integer of 1 to 4; and R.sup.3 is hydrogen, lower alkyl or an ester residue which can be removed under physiological conditions); R.sup.1 is hydrogen or lower alkyl; and R.sup.2 is hydrogen atom or lower alkyl.

Abstract: A compound represented by the formula (I) is disclosed. The compound of the formula (I) is useful as a fine particle drug carrier. When used as the fine particle drug carrier, the compound efficiently avoids a reticuloendothelial system and has a long circulation time in blood.

Abstract: A .gamma.-diketone compound represented by the following formula (I) and a pharmaceutically acceptable salt and solvate thereof having platelet aggregation inhibitory activity is disclosed: ##STR1## wherein B is --Z--(CH.sub.2).sub.q COOR.sup.

Abstract: A compound represented by the general formula (I) and a pharmaceutically acceptable salt and solvate thereof having an effect for inhibiting the agglutination of platelets is disclosed: ##STR1## wherein R.sup.1 represents a group --W--(CH.sub.2).sub.i --COOR.sup.3,R.sup.2 represents a hydrogen atom or a group --W--(CH.sub.2).sub.i --COOR.sup.3 or --OR.sup.4,X represents --CH.dbd. or --N.dbd.,Y represents(i) a group --(CO).sub.k --N(R.sup.5)--Z--, wherein Z represents a bond or a group --(CH.sub.2).sub.m --CO-- or a group --(CH.sub.2).sub.m --CHR.sup.6 --,(ii) a group --(CH.sub.2).sub.m --N(R.sup.5)--(CO).sub.k --, or(iii) a group --(CO).sub.k --Het, wherein Het represents a five- or six-membered heterocyclic ring comprising a nitrogen atom,A represents(i) the following groups (II), (III) or (IV) ##STR2## B represents a bond, C.sub.1-6 alkylene or C.sub.2-6 alkenylen.

Abstract: The tricyclic benzazepine and benzothiazepine derivatives represented by the formula (I) and pharmacologically acceptable salts thereof are disclosed. ##STR1## wherein Z represents CO, --CR.sup.6 R.sup.7 -- or --S(O).sub.n, R represents hydrogen, alkyl, phenylalkyl, or a protective group of a triazole ring, R.sup.1 -R.sup.5 represent hydrogen, alkyl, alkenyl, alkoxy, amino, oxim or hydroxyl. These compounds have anti-allergic effect and are useful for the treatment and prophylaxis of allergic diseases.

Abstract: Compounds represented by the following formula (I), that is, cephem derivatives having substituted or unsubstituted imidazo[5,1-b]thiazolium-6-yl as a substituent at the 3-position of the cephem ring: ##STR1## wherein X represents CH or N, R.sup.1 represents H, alkyl, alkenyl or the like, and R.sup.2, R.sup.3, R.sup.4 and R.sup.5 represent H, alkyl, carbamoyl, amino or the like. The above compounds have excellent antibacterial activity, and useful as medicines for the treatment of various infectious diseases caused by bacteria.

Abstract: Compounds represented by the following formula (I), that is, cephem derivatives having substituted or unsubstituted 3-(imidazo[5,1-b]thiazolium-6-yl)-1-propenyl as a substituent at the 3-position of the cephem ring: ##STR1##

Abstract: Compounds represented by the formula (I) and pharmacologically acceptable salts thereof: ##STR1## These compounds have little extrapyramidal effect and thus are effective as an anti-psychotic agent having few side effects.

Abstract: A compound represented by the general formula (I) and a pharmaceutically acceptable salt and solvate thereof having an effect for inhibiting the agglutination of platelets is disclosed: ##STR1## wherein R.sup.1 represents a group --W--(CH.sub.2).sub.i --COOR.sup.3,R.sup.2 represents a hydrogen atom or a group --W--(CH.sub.2).sub.i --COOR.sup.3 or --OR.sup.4,X represents --CH.dbd. or --N.dbd.,Y represents(i) a group --(CO).sub.k --N(R.sup.5)--Z--, wherein Z represents a bond or a group --(CH.sub.2).sub.m --CO-- or a group --(CH.sub.2).sub.m --CHR.sup.6 --,(ii) a group --(CH.sub.2).sub.m --N(R.sup.5)--(CO).sub.k --, or(iii) a group --(CO).sub.k -Het, wherein Het represents a five- or six-membered heterocyclic ring comprising a nitrogen atom,A represents(i) the following groups (III) or (IV) ##STR2## B represents a bond, C.sub.1-6 alkylene or C.sub.2-6 alkenylen.

Abstract: (-)-Ritodrine, that is (-)-erythro-1-(p-hydroxyphenyl)-2-[2-(p-hydroxyphenyl)ethylamino]-1-propan ol or a salt thereof substantially free from the (+)-isomer is disclosed. The compound has a strong suppressive effect on uterine contraction in comparison with (.+-.)-ritodrine and (+)-ritodrine and has the same level of toxicity as these compounds, so that it can be used as a therapeutic agent of threatened premature birth and threatened abortion as well as a therapeutic agent of dysmenorrhea having a high safety.

Abstract: The present invention relates to an apparatus for determining the presence or absence of a target analyte in a liquid sample, comprising:(i) a container capable of accommodating the liquid sample and having a transparent portion; and(ii) an insertion member which is capable of being inserted into the container comprising;a porous member which has a main surface and a reverse surface and which has on the main surface a substance capable of specifically binding to the target analyte; andan absorbent bonded to the reverse surface of the porous member;the porous member being supported in the insertion member whereby, when the insertion member is inserted into the container, the main surface can be observed from the outside of the container through the transparent portion of the vessel and the liquid sample is absorbed into the absorbent through the porous member.According to the analyzer of the present invention, the presence or absence of a target analyte in a sample can be easily determined.

Abstract: The invention provides compounds represented by the following formula (I) ##STR1## or a pharmaceutically acceptable salts thereof wherein A represents ##STR2## B represents a carboxy or tetrazolyl group; and X represents --O--, --NH-- or --S(O).sub.t --.The compounds possess angiotensin II antagonism, and may be used as an antihypertensive agent, a therapeutic agent to congestive heart failure, an antianxiety agent and a cognitive enhancing agent.

Abstract: A 4-acyloxyquinoline derivative represented by the general formula (I): ##STR1## wherein R.sup.1 represents a hydrogen atom, a C.sub.1 -C.sub.18 alkyl, C.sub.2 -C.sub.18 alkenyl, C.sub.3 -C.sub.10 cycloalkyl which may be optionally substituted, phenylloweralkyl, phenoxyloweralkyl, aryl group, a group OR.sup.4, where R.sup.4 represents a lower alkyl or aryl group, or a group ##STR2## where X represents an oxygen or a sulphur atom; R.sup.2 represents a hydrogen atom, a lower alkyl alkyl group or a group --COOR.sup.5 where R.sup.5 represents a hydrogen atom or a lower alkyl group; R.sup.3 represents a hydrogen atom, a C.sub.1 -C.sub.10 alkyl or C.sub.2 -C.sub.10 alkenyl group, provided that R.sup.1 does not represent OR.sup.4 when R.sup.2 is a hydrogen atom and R.sup.3 is methyl; R.sup.2 and R.sup.3 together represent a group (CH.sub.2).sub.

Abstract: A thiazole or imidazole derivative having the general formula (I): ##STR1## wherein: R.sup.1 and R.sup.2, which may be the same or different, each independently represent a hydrogen atom, or a phenyl or heteroaryl group, or R.sup.1 and R.sup.2 may together form a benzene ring which may be optionally substituted by a halogen atom or a lower alkyl optionally substituted by a halogen atom, lower alkoxy or nitro group;A represents a sulfur atom or --NH--;B represents a lower alkoxy group optionally substituted by a halogen atom; a five- or six-membered saturated heterocyclic ring containing one nitrogen or oxygen atom which ring may be optionally substituted; a six-membered saturated heterocyclic ring containing one oxygen atom plus one nitrogen atom; a group --XR.sup.3 where X represents a group --NR.sup.4 wherein R.sup.3 and R.sup.4, which may be the same or different, each independently represent a lower alkyl group; or a group --NHC(.dbd.Y)R.sup.5 where Y represents an oxygen or sulfur atom or a group .dbd.